8-K: Kyverna Therapeutics Appoints Marc Grasso as New Chief Financial Officer to Drive Strategic Growth

Kyverna Therapeutics, a clinical-stage biopharmaceutical company, has appointed Marc Grasso, M.D., as its new Chief Financial Officer, effective June 30, 2025, succeeding Ryan Jones who transitions to a strategic advisor role.

Summary

• Kyverna Therapeutics, Inc. appointed Marc Grasso, M.D., as Chief Financial Officer, principal financial officer, and principal accounting officer, effective June 30, 2025.
• Dr. Grasso's initial annualized salary is $510,000.
• He is eligible for an annual performance bonus of up to 40% of his base salary, which will not be pro-rated for 2025 and will be fixed at target for 2025.
• Dr. Grasso will receive a sign-on bonus of $250,000, with $100,000 paid on or after June 30, 2025, and the remaining $150,000 on January 1, 2026, subject to continued employment; the full $250,000 is repayable if he voluntarily resigns prior to the first anniversary of the effective date.
• He will be granted an option to purchase 450,000 shares of common stock, vesting over four years, with 25% vesting on the one-year anniversary of the effective date and 1/48th monthly thereafter.
• Ryan Jones ceased serving as Chief Financial Officer, principal financial officer, and principal accounting officer, effective June 30, 2025.
• Mr. Jones will transition to a strategic advisor role to Dr. Grasso from June 30, 2025, through August 8, 2025, which may be extended by mutual written agreement.
• During the advisor period, Mr. Jones will continue to receive his current salary ($375,000 annually), vest in outstanding equity, and remain eligible for benefits.
• Upon re-execution of a letter agreement within 30 days of the advisor period termination, Mr. Jones will receive 9 months of base salary continuation, up to 9 months of COBRA premium reimbursement, continued equity vesting until the later of 9 months post-separation or April 30, 2026, and his pro-rated 2025 target bonus ($150,000).
• The Company will directly pay Mr. Jones's actual, reasonable, and documented attorneys' fees incurred in connection with the negotiation and documentation for the letter agreement, not to exceed $15,000.

Sentiment

Score: 7

Explanation: The announcement of a new CFO with strong industry and capital markets experience is a positive strategic move for a clinical-stage company. The structured transition for the outgoing CFO also indicates good corporate planning. No negative financial or operational news is present.

Positives

• Appointment of an experienced Chief Financial Officer, Marc Grasso, M.D., who brings over 25 years of public company, capital markets, and investment banking expertise.
• Dr. Grasso's background includes CFO roles at clinical-stage biotechnology companies Alector, Inc. and Kura Oncology, Inc., and leadership in investment banking at Stifel, UBS, and Leerink Swann, which is highly relevant for Kyverna's strategic goals.
• The structured transition plan for the outgoing CFO, Ryan Jones, to a strategic advisor role ensures continuity and a seamless handover of responsibilities.

Risks

• Forward-looking statements are subject to various important factors, including uncertainties related to market conditions, and other factors discussed in Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Kyverna Therapeutics aims to accelerate its clinical development and commercialization efforts, advance its mission to bring the transformative potential of CAR T-cell therapy to patients with autoimmune diseases, and potentially bring the first CAR T-cell therapy for autoimmune disease to market. The company also plans to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process and explore next priority indications for late-stage development based on KYSA trials and investigator-initiated trials.

Management Comments

• "We are excited to welcome Marc, an accomplished life-sciences leader with a proven track record working in capital markets and driving financial discipline and operational execution in maturing public companies." Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.
• "As we continue to accelerate our clinical development and commercialization efforts, Marcs leadership will be instrumental in supporting our next phase of growth and advancing our mission to bring the transformative potential of CAR T-cell therapy to patients with autoimmune diseases." Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.
• "On behalf of the Kyverna leadership team, Id also like to thank Ryan, one of Kyvernas first employees, for the significant contributions he has made throughout his tenure with the Company." Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.
• "I am thrilled to join Kyverna at this dynamic time and help accelerate the next critical phase of growth for the Company." Dr. Marc Grasso.
• "I look forward to leveraging my experience to contribute to Kyvernas goal of bringing the first CAR T-cell therapy for autoimmune disease to market and drive business and financial strategies that support the Companys mission." Dr. Marc Grasso.

Industry Context

The appointment of a CFO with extensive capital markets and investment banking experience, particularly in the biotechnology sector, suggests Kyverna is positioning itself for significant financial activities, potentially including further capital raises or strategic partnerships, common for clinical-stage biopharmaceutical companies advancing therapies like CAR T-cell therapy for autoimmune diseases. This aligns with the industry trend of companies seeking strong financial leadership to navigate complex clinical development and commercialization pathways.

Comparison to Industry Standards

• The compensation package for the new CFO, including a base salary of $510,000, a 40% target bonus, and a 450,000 share option grant, appears competitive for a CFO at a clinical-stage biopharmaceutical company, especially one focused on advanced cell therapies like CAR T-cell.
• The severance and transition arrangements for the outgoing CFO, Ryan Jones, including 9 months of base salary and continued equity vesting, are standard practice in executive transitions to ensure smooth handover and mitigate potential disputes.
• Dr. Grasso's prior roles at Alector, Inc. and Kura Oncology, Inc. (both clinical-stage biotech companies) and his investment banking background at Stifel, UBS, and Leerink Swann are highly relevant and align with the profile typically sought for a CFO in the life sciences sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to the appointment of an experienced CFO who can drive financial discipline and strategic growth, potentially enhancing investor confidence and future capital allocation.
• Employees: Ryan Jones transitions to a strategic advisor role, indicating a managed change rather than an abrupt termination, which could be positive for employee morale. New CFO brings new leadership.
• Customers/Patients: Indirect positive impact as the new CFO's expertise is expected to support accelerated clinical development and commercialization efforts, potentially bringing new therapies to market faster.

Next Steps

• Accelerate clinical development and commercialization efforts.
• Advance the mission to bring CAR T-cell therapy to patients with autoimmune diseases.
• Bring the first CAR T-cell therapy for autoimmune disease to market.
• Increase patient reach with KYV-102 using proprietary whole blood rapid manufacturing process.
• Inform next priority indications for late-stage development based on KYSA trials and investigator-initiated trials.

Key Dates

Recommendation

Keywords

Kyverna Therapeutics, CFO appointment, Marc Grasso, Ryan Jones, Chief Financial Officer, biopharmaceutical, cell therapy, autoimmune diseases, executive change, corporate governance, Nasdaq, KYTX